Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

Phase 3

Recruiting

Conditions: Metastatic Non-squamous Lung Cancer

Interventions: Drug: Pembrolizumab 200 mg Q6W
Drug: Pemetrexed 500 mg/m^2 Q3W
Drug: Pembrolizumab 200 mg Q3W or 400 mg Q6W

First Posted Date: 2023-01-20

Last Posted Date: 2024-12-04

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1166

Registration Number: NCT05692999

Locations: 🇫🇷
Centre Hospitalier de Carcassonne, Carcassonne, Aude, France
🇫🇷
Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, Bas-Rhin, France
🇫🇷
Clinique Sainte Anne - Strasbourg, Strasbourg, Bas-Rhin, France

and more 27 locations

MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2

Not Applicable

Recruiting

Conditions: Leukemia
Solid Tumor

Interventions: Biological: Solid tumor and CT DNA

First Posted Date: 2023-01-20

Last Posted Date: 2024-10-18

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1800

Registration Number: NCT05691608

Locations: 🇫🇷
CHU Angers, Angers, France
🇫🇷
CHU Besançon, Besançon, France
🇫🇷
CHU Pellegrin, Bordeaux, France

and more 23 locations

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Phase 2

Recruiting

Conditions: KRAS P.G12C
Non Small Cell Lung Cancer

Interventions: Drug: Sotorasib 120Mg Tab

First Posted Date: 2022-11-30

Last Posted Date: 2024-12-04

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 40

Registration Number: NCT05631249

Locations: 🇫🇷
Hôpital Paris Saint Joseph, Paris, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
AP-HM Hôpital Nord, Marseille, France

and more 2 locations

An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors

Not Applicable

Recruiting

Conditions: Hematologic Cancer
Solid Tumor, Childhood
Solid Tumor, Adult

Interventions: Procedure: Tumor biopsy
Procedure: Blood sample
Procedure: Bone marrow sample

First Posted Date: 2022-08-01

Last Posted Date: 2024-08-14

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 160

Registration Number: NCT05481502

Locations: 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val De Marne, France

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Phase 3

Recruiting

Conditions: Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant

Interventions: Drug: ONC201
Drug: Everolimus
Radiation: Radiotherapy

First Posted Date: 2022-07-27

Last Posted Date: 2024-12-13

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 409

Registration Number: NCT05476939

Locations: 🇩🇰
Aarhus Universitetshospital Skejby, Aarhus, Denmark
🇪🇸
Hospital Vall D´Hebron, Barcelona, Spain
🇪🇸
Hospital Universitario y Politécnico de La Fe, Valence, Spain

and more 39 locations

Implementing Precision Medicine in cOmmunity HospiTALs

Not Applicable

Recruiting

Conditions: Metastatic Cancer

Interventions: Biological: biopsy liquid

First Posted Date: 2022-03-16

Last Posted Date: 2024-08-14

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1500

Registration Number: NCT05283044

Locations: 🇫🇷
Centre Hospitalier, Pau, France
🇫🇷
Hôpital Nord-Ouest Villefranche-sur-Saône, Villefranche-sur-Saône, France
🇫🇷
Hôpital Saint-Joseph, Paris, France

and more 17 locations

Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers

Not Applicable

Active, not recruiting

Conditions: Advanced, Pretreated Solid Tumors

Interventions: Procedure: Biopsy

First Posted Date: 2022-03-07

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 61

Registration Number: NCT05267912

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)

Phase 2

Recruiting

Conditions: Early Small (cT1N0) Triple Negative Breast Cancer

Interventions: Drug: Durvalumab

First Posted Date: 2022-01-31

Last Posted Date: 2024-07-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 200

Registration Number: NCT05215106

Locations: 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Centre Léon Berard, Lyon, France

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Atezolizumab Injection
Drug: Pertuzumab
Drug: Trastuzumab
Drug: Bevacizumab

First Posted Date: 2022-01-06

Last Posted Date: 2024-04-18

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 185

Registration Number: NCT05180006

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

Not Applicable

Terminated

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Dietary Supplement: Discontinuous ketogenic diet
Dietary Supplement: Continuous ketogenic diet
Dietary Supplement: beta-hydroxybutyrate (BHB) supplementation

First Posted Date: 2021-11-12

Last Posted Date: 2024-12-05

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 3

Registration Number: NCT05119010

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val-de-Marne, France
🇫🇷
Hôpital Européen Georges Pompidou, Paris, France
🇫🇷
Hôpitaux Cochin-Port-Royal, Paris, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy